1. Medtech Insight
  2. >>Archive

Johnson and Johnson combines Biosense with Cordis subsidiary:

Johnson & Johnson is to merge its Cordis Webster company with Biosense, an acquisition from last October. According to J&J, the move means the company, now to be known as Biosense Webster, will "better serve the needs of cardiologists" and apply its medical sensor technology. Cordis Webster was acquired in 1996 as part of the Cordis deal. The new company's worldwide president will be James Dennis, formerly president of St Jude's cardiac rhythm management division.

Johnson & Johnson is to merge its Cordis Webster company with Biosense, an acquisition from last October. According to J&J, the move means the company, now to be known as Biosense Webster, will "better serve the needs of cardiologists" and apply its medical sensor technology. Cordis Webster was acquired in 1996 as part of the Cordis deal. The new company's worldwide president will be James Dennis, formerly president of St Jude's cardiac rhythm management division.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

A Deregulated Medtech Sector Could Flourish In Merz’s Industry-Friendly Germany

 
• By Ashley Yeo

Less bureaucracy, no more national supply chain law, framework agreements and competition for direct reimbursement of medtech innovations are among the positive changes the local medtech industry might expect as Germany’s new government gets down to work. Life sciences lawyer Gunnar Sachs offers a view from the ground.

Danaher Faces $350M Tariff Hit, But Says It’s Ready To Absorb The Blow

 
• By Shubham Singh

Despite Danaher’s confident outlook, the company acknowledged near-term profitability fluctuations, particularly in the second quarter. Matt McGrew, Danaher’s CFO, clarified during the company’s first-quarter earnings call on 22 April, that expected operating margin softness in the second quarter – forecast at 25.5% – was not related to tariffs, but to seasonal dynamics in its respiratory diagnostics business.